Precision BioSciences to Participate in the Jefferies Virtual Healthcare Conference
DURHAM, N.C.--(BUSINESS WIRE)--May 26, 2021--
Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and co-founder, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference being held from June 1-4, 2021.
Details for the fireside chat are below:
Jefferies Virtual Healthcare Conference
Date: Wednesday, June 2, 2021
Time: 1:30 PM ET
A live webcast of the fireside chat will be accessible on the Company’s website www.precisionbiosciences.com, under the Investors & Media section. An archived replay of the webcasts will be available for approximately 30 days.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210526005350/en/
CONTACT: Investor Contact:
Interim Chief Financial Officer
Senior Director, Corporate Communications
KEYWORD: NORTH CAROLINA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH GENETICS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY
SOURCE: Precision BioSciences Inc.
Copyright Business Wire 2021.
PUB: 05/26/2021 07:00 AM/DISC: 05/26/2021 07:03 AM